centerforbiosimilars12h
3 Ustekinumab Biosimilars Launch on US Market
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
centerforbiosimilars1d
Lisa Lasita, PharmD, MBA
Study Confirms CT-P42 Therapeutic Equivalence to Reference Aflibercept in DME ...
centerforbiosimilars1d
Josh Canavan, PharmD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars1d
Dinakaran Balasubramanian
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars2d
Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy ...
centerforbiosimilars2d
Skylar Jeremias
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key ...
centerforbiosimilars2d
Derek Burns, PharmD, MBA, BCPS, BCSCP
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars2d
Peter Pitts
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars2d
Nancy J. Globus, PharmD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars2d
Lana Pine
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...